Articles that tag JANX but are mainly about other companies.
Modest 2.2% daily gain but negative 9% monthly return. Consensus EPS estimate improved 5.7% over the past month, but company remains unprofitable with a Zacks Rank #3 (Hold) rating, indicating mixed outlook.
Early-stage prostate cancer pipeline with JANX007 in phase Ib development and multiple other candidates in phase I studies. No approved prostate cancer drugs yet, making this more speculative. However, strong cash position of $970.9M provides financial capacity to advance programs. Programs are still in early clinical stages.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
